Astrazeneca Pharma India announced that Jes�s Diaz-Ropero Esteso has resigned from the position of Non-Executive Director of AstraZeneca Pharma India and consequently from the Board Committee(s) on which he served, with immediate effect, due to a transition from current responsibilities. Powered by Capital Market - Live News

The board of Astrazeneca Pharma India has appointed Sandhya Tejaswini Amanna as Director - Legal, with effect from 18 March 2026.Powered by Capital Market - Live News

Net profit of Astrazeneca Pharma India rose 5.64% to Rs 32.59 crore in the quarter ended December 2025 as against Rs 30.85 crore during the previous quarter ended December 2024. Sales rose 38.90% to Rs 611.57 crore in the quarter ended December 2025 as against Rs 440.29 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales611.57440.29 39 OPM %7.3317.49 - PBDT48.9084.64 -42 PBT45.0675.57 -40 NP32.5930.85 6 Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live News

Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma� whereas Sun Pharma will promote and distribute the therapy as Gimliand�. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.Powered by Capital Market - Live News